Table 1.
Description of included randomized controlled trials
| Author | Sample size (C/M) | Therapy period | Virological end-point | Follow-up period(m) | Study design | Grade |
| Lee 2008 | 62(31/31) | Tα1 24w+LAM 52w | HBV DNA(-) | 0 | RCT | B |
| Li 2005 | 68(34/34) | Tα1 52w+LAM 52w | HBV DNA(-) | 0 | RCT | C |
| Liang 2006 | 72(36/36) | Tα1 6m+LAM 12m | HBV DNA(-) | 12 | RCT | B |
| Lin 2003 | 72(35/37) | Tα1 26w+LAM 52w | HBV DNA(-) | 12 | RCT | B |
| Liu 2005 | 98(49/49) | Tα1 26w+LAM52w | HBV DNA(-) | 0 | RCT | C |
| Sun 2008 | 81(41/40) | Tα1 6m+LAM12m | HBV DNA(-) | 12 | RCT | C |
| Wu 2002 | 60(29/31) | Tα1 6m+LAM12m | HBV DNA(-) | 12 | RCT | B |
| Zhao 2007 | 68(33/35) | Tα1 6m+LAM12-18m | HBV DNA(-) | 0 | RCT | C |
Abbreviations C: combination therapy; M: monotherapy; Tα1: thymosin alpha 1; LAM: lamivudine; w: weeks; m: months; RCT: randomized controlled trail.